Literature DB >> 9336391

Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade.

L V d'Uscio1, M Barton, S Shaw, P Moreau, T F Lüscher.   

Abstract

The involvement of endothelin in salt-induced hypertension is unclear. In the Dahl rat model, we studied the effects of a selective endothelin-subtype A (ET[A]) receptor antagonist, LU135252, on blood pressure, vascular structure, and function. Dahl salt-sensitive and salt-resistant rats were treated for 8 weeks with 4% NaCl alone or in combination with LU135252 taken orally (60 mg/kg per day). The geometry and reactivity of basilar and mesenteric arteries were studied in vitro under perfused and pressurized conditions using a video dimension analyzer. Chronic salt administration increased systolic blood pressure by 37 +/- 3 mm Hg and media-lumen ratio of the basilar and mesenteric arteries in salt-sensitive rats (P<.05). These structural changes were caused by eutrophic remodeling in basilar and hypertrophic remodeling in mesenteric arteries. Endothelium-dependent relaxations to acetylcholine and contractions to endothelin-1 were impaired in mesenteric arteries of salt-sensitive rats on a high NaCl diet. LU135252 prevented part of the increase in systolic blood pressure and structural and functional alterations but increased plasma endothelin 1 levels (P<.05 versus salt-treated, saltsensitive rats). LU135252 had no effect on these parameters in salt-resistant rats. These findings suggest that the long-term pressor effect of salt administration is mediated in part by the action of endogenous endothelin acting via ET(A) receptors. Thus, chronic ET(A) receptor blockade may be useful therapeutically to lower arterial pressure and prevent endothelial dysfunction and hypertrophic remodeling of resistance arteries in salt-sensitive forms of hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336391     DOI: 10.1161/01.hyp.30.4.905

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

Review 1.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

3.  Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma.

Authors:  M Emre; S Orgül; T Haufschild; S G Shaw; J Flammer
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

4.  Endothelium-specific amyloid precursor protein deficiency causes endothelial dysfunction in cerebral arteries.

Authors:  Livius V d'Uscio; Tongrong He; Anantha V Santhanam; Zvonimir S Katusic
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-29       Impact factor: 6.200

Review 5.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 6.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development.

Authors:  Anthony J Donato; Lisa A Lesniewski; Deborah Stuart; Ashley E Walker; Grant Henson; Lise Sorensen; Dean Li; Donald E Kohan
Journal:  Life Sci       Date:  2014-01-08       Impact factor: 5.037

8.  Plasma C-terminal pro-endothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension.

Authors:  M A Al-Omari; M Khaleghi; T H Mosley; N G Morgenthaler; J Struck; A Bergmann; I J Kullo
Journal:  J Hum Hypertens       Date:  2010-02-25       Impact factor: 3.012

Review 9.  Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2.

Authors:  Matthias Hermann; Frank Enseleit; Frank T Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

10.  Protein restriction during pregnancy induces hypertension and impairs endothelium-dependent vascular function in adult female offspring.

Authors:  Kunju Sathishkumar; Rebekah Elkins; Uma Yallampalli; Chandra Yallampalli
Journal:  J Vasc Res       Date:  2008-10-29       Impact factor: 1.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.